There were 2 later studies, the 2009 Cancer and Leukemia Group B (CALGB) 89803 trial13 and 2010 Pan-European Trial in Adjuvant Colon Cancer (PETACC)-3,14 that were then unable to replicate a link between KRAS variant status and clinical outcomes. This evidence concerns the gene KRAS and cancer.